December 15, 2010

Novartis on Wednesday announced that its merger agreement with Alcon has been settled to the tune of $12.9 billion. The new $8.7 billion Alcon eye care division, which includes CIBA Vision and selected ophthalmic medicines, will be led by current Alcon president and CEO Kevin Buehler.

January 3, 2010

With an eye to the future, Novartis brass envisions a growth arena driven by the...